ATE314462T1 - Verfahren zur transformation dendritischer zellen und aktivierung von t zellen - Google Patents

Verfahren zur transformation dendritischer zellen und aktivierung von t zellen

Info

Publication number
ATE314462T1
ATE314462T1 AT97905877T AT97905877T ATE314462T1 AT E314462 T1 ATE314462 T1 AT E314462T1 AT 97905877 T AT97905877 T AT 97905877T AT 97905877 T AT97905877 T AT 97905877T AT E314462 T1 ATE314462 T1 AT E314462T1
Authority
AT
Austria
Prior art keywords
cells
cell
activation
dendritic
transforming
Prior art date
Application number
AT97905877T
Other languages
English (en)
Inventor
Patrick Hwu
Mark Reeves
Steven A Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE314462T1 publication Critical patent/ATE314462T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464499Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/22Colony stimulating factors (G-CSF, GM-CSF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97905877T 1996-02-08 1997-02-07 Verfahren zur transformation dendritischer zellen und aktivierung von t zellen ATE314462T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1143396P 1996-02-08 1996-02-08
PCT/US1997/002063 WO1997029183A2 (en) 1996-02-08 1997-02-07 Methods and compositions for transforming dendritic cells and activating t cells

Publications (1)

Publication Number Publication Date
ATE314462T1 true ATE314462T1 (de) 2006-01-15

Family

ID=21750351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905877T ATE314462T1 (de) 1996-02-08 1997-02-07 Verfahren zur transformation dendritischer zellen und aktivierung von t zellen

Country Status (7)

Country Link
EP (1) EP0879281B1 (de)
JP (1) JP2000505650A (de)
AT (1) ATE314462T1 (de)
AU (1) AU730537B2 (de)
CA (1) CA2245170A1 (de)
DE (1) DE69734974D1 (de)
WO (1) WO1997029183A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227065A1 (en) * 1995-07-21 1997-02-06 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7351546B2 (en) 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1046911A1 (de) * 1999-04-23 2000-10-25 Universiteit van Amsterdam Methoden zur Identifizierung von Substanzen, die zelluläre Reaktionen auslösen können
EP1185627A2 (de) * 1999-06-01 2002-03-13 Cornell Research Foundation, Inc. Aktivierung von dendritischen zellen zur verstärkung der immunität
FR2795415B1 (fr) * 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
DK1224264T3 (da) * 1999-10-15 2010-05-10 Baylor Res Inst Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
AU2002306766A1 (en) * 2001-03-16 2002-10-03 Johns Hopkins University School Of Medicine Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
FR2824567B1 (fr) 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP1450828B1 (de) * 2001-08-17 2015-04-01 Roger Williams Hospital In situ-immunisierung
US7955845B2 (en) 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2006124700A2 (en) 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
US20110313229A1 (en) * 2008-07-24 2011-12-22 Kiminobu Sugaya Therapy Targeting Cancer Stem Cells
EP3376225A1 (de) * 2010-08-06 2018-09-19 Ludwig-Maximilians-Universität München Identifizierung von t-zell-zielantigenen
EP3295945A1 (de) * 2012-03-13 2018-03-21 HLI Cellular Therapeutics, LLC Modifizierte erythrozytenvorläuferzellen und verwendungen davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
KR950700403A (ko) * 1992-03-04 1995-01-16 죤 제이. 쉬바르츠 조혈 간세포의 배양 및 그것의 유전공학(culturing of hematopoietic stem cells and their genetic engineering)
EP0563485A1 (de) * 1992-03-30 1993-10-06 Schering-Plough In-vitro-Erzeugung von menschlichen dendritischen Zellen
JPH09500013A (ja) * 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
JP3957746B2 (ja) * 1994-06-15 2007-08-15 ノバルティス アクチエンゲゼルシャフト 骨髄始原細胞および/またはリンパ系始原細胞について富化される細胞集団、ならびに製造方法および使用方法
CA2227065A1 (en) * 1995-07-21 1997-02-06 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity

Also Published As

Publication number Publication date
EP0879281B1 (de) 2005-12-28
AU2266097A (en) 1997-08-28
CA2245170A1 (en) 1997-08-14
WO1997029183A3 (en) 1997-12-18
AU730537B2 (en) 2001-03-08
DE69734974D1 (de) 2006-02-02
JP2000505650A (ja) 2000-05-16
WO1997029183A2 (en) 1997-08-14
EP0879281A2 (de) 1998-11-25

Similar Documents

Publication Publication Date Title
ATE314462T1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
NL300307I1 (nl) Werkwijzen voor de replicatie van influenzavirussen in celkweek en de influenzavirussen die verkrijgbaar zijn met behulp van de werkwijze
DE60224291D1 (de) System zur antikörperexpression und- synthese
EP1194164B8 (de) Prion protein peptide und deren verwendung
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
AU2001294541A1 (en) Mammalian genes; related reagents and methods
ES2113088T3 (es) Metodo de entrega de agentes a celulas diana.
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
DE69609188D1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
GB2428042A (en) P gingivalis vaccine
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
AR022236A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
WO1999036568A3 (de) Verfahren zum identifizieren von t-zell-stimulierenden proteinfragmenten
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
AU1060397A (en) High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
BR9713450A (pt) Quimiocinas de mamìfero
WO2002068475A3 (es) Composicion farmaceutica de fragmentos f(ab)2 de anticuerpos y un proceso para su preparacion
EP1986011A3 (de) Durch eine CD4+-T-Lymphozyten fördernde Krankheit erkannte Peptidepitope
WO2003089651A3 (en) Assay for quantitating secreted antibodies in lymphocytes supernatant

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties